Bio-Path Holdings (BPTH) Receives EMA Orphan Drug Designation for BP1001 as AML Treatment
Tweet Send to a Friend
Bio-Path Holdings, Inc., (Nasdaq: BPTH) announced that the European Medicines Agency (EMA) granted orphan drug designation to BP1001 for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
